JPRN-UMIN000005143RecruitingPhase 1
A Phase 2 study of Carboplatin plus Pemetrexed plus Bevacizumab as first-line therapy for stage3B/4 non-squamous non-small-cell lung cancer - A Phase 2 study of Carboplatin plus Pemetrexed plus Bevacizumab as first-line therapy for stage3B/4 non-squamous non-small-cell lung cancer
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Dokkyo Medical University
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Uncontrolled infection or Serious medical complications 2)Uncontrolled pleural effusion or ascites 3)Brain metastases 4)Serious disease condition 5)Uncontrolled diabetes mellitus 6)Therapeutic anticoagulopathy 7)Uncontrolled hyper tension 8)Current or previous history of GI perforation 9)interstitial lung disease or fibroid lung 10)history of drug-induced interstitial lung diseas 11)Current or previous history of hemoptysis 12)history of hemoptysis 13)Scheduling operation for examination time 14)Treatment history of carboplatin,pemetrexed,bevacizumab 15)Drug allergens 16)Multiple primary cancer 17)Serious psychiatric illness or psychological symptom 18)Women who are pregnant, lactating or with childbearing potential. 19)Ineligible based on decision of an investigator.
Investigators
Similar Trials
Completed
Phase 2
A phase II study of carboplatin plus pemetrexed followed by gefitinib for stage IIIB/IV non-small cell lung cancer with EGFR mutationon-small cell lung cancer with EGFR mutationJPRN-UMIN000003354Kanagawa Cancer Center60
Completed
Phase 2
Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation.on-squamous Non-small-cell Lung CancerJPRN-UMIN000004731Central Japan Lung Study Group27
Recruiting
Phase 2
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancer (EGFR mutation status Negative)JPRN-UMIN000005991Toho University Omori Medical Center35
Completed
Phase 2
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed Plus Bevacizumab in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000003770Osaka Lung Cancer Study Group40
Active, not recruiting
Not Applicable
Phase 2 Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung CancerPatients with a histologic and/or cytologic diagnosis of LS-SCLC who are naïve to prior chemotherapy and/or thoracic radiotherapyMedDRA version: 9.1Level: LLTClassification code 10041069Term: Small cell lung cancer limited stageEUCTR2007-000913-13-GBEli Lilly and Company Limited55